Advise neomycin-sensitive patients to avoid the ... Ciloxan® ophthalmic ointment and solution (cipro-floxacin), Vigamox® ophthalmic solution (moxifloxacin), Ocuflox® ophthalmic solution ...

The phase 3 trial observed the treatment of chronic night driving impairment in keratorefractive patients with reduced ...

The active ingredient in Tryptyr is acoltremon, an agonist of transient receptor potential melastatin 8 thermoreceptors.

Phentolamine Ophthalmic Solution 0.75% is designed to reduce pupil diameter through a sympatholytic mechanism of action that avoids engaging the ciliary muscle, potentially reducing risks such as ...

These disturbances can significantly impair night driving and daily functioning in dim environments. Phentolamine Ophthalmic Solution 0.75% is designed to reduce pupil diameter through a sympatholytic ...

The U.S. Food and Drug Administration has approved the first-in-class TRPM8 receptor agonist Tryptyr (acoltremon ophthalmic ...

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms ...

In pivotal Phase 3 trials, TRYPTYR demonstrated rapid natural tear production as early as Day 1 1-2 TRYPTYR is a first-in-class TRPM8 receptor agonist that rapidly stimulates natural tear ...

Over-the-counter ophthalmic products were voluntarily recalled due to a manufacturing deviation discovered during a U.S. Food and Drug Administration audit, a notice says. Pharmaceutical ...